Hematopoietic stem cell therapy for malignant diseases

References

• Appelbaum F. R., Thomas E. D. Treatment of acute leukemia in adults with chemoradiotherapy and bone marrow transplantation. Cancer 1985; 55: 2202–09
   Google Scholar
• Sinkovics J. G., Shullenberger C. C. Effect of hematopoietic chimerism on the course of Rauscher's viral mouse leukemia. Proc Am Assoc Cancer Res 1963; 4: 62–72
   Google Scholar
• Boranic M., Tonkovic I. Time pattern of the antileukemia effect of graft‐vs‐host reaction in mice. I. Cellular events. Cancer Res 1971; 31: 1140–7
   PubMed Web of Science ®Google Scholar
• Weiden P. L., Fluornoy N., Sanders J. E., Sullivan K. M., Thomas E. D. Anti‐leukemic effect of graft‐versus‐host disease contributes to improved survival after allogeneic marrow transplantation. Transplantation 1981; 13: 248–51
   Google Scholar
• Slavin S., Or R., Naparstek E., Ackerstein A., Weiss L. Cellular‐mediated immunotherapy of leukemia in conjunction with autologous and allogeneic bone marrow transplantation in experimental animals and man. Blood 1988; 72 suppl 1: 407a
   Google Scholar
• Slavin S., Naparstek E., Nagler A., Ackerstein A., Kapelushnik J., Brautbar C., et al. Allogeneic cell therapy for relapsed leukemia following bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol 1995; 23: 1553–62
   PubMed Web of Science ®Google Scholar
• Slavin S., Naparstek E., Nagler A., Akerstein A., Samuel S., Kapelushnik J., et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin‐2 to treat leukemia relapse after post allogeneic bone marrow transplantation. Blood 1996; 87: 2195–204
   PubMed Web of Science ®Google Scholar
• Gratwohl A., Hermans J., Goldman J. M., Arcese W., Carreras E., Devergie A., et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998; 352: 1087–92
   PubMed Web of Science ®Google Scholar
• Passweg J. R., Rowlings P. A., Armitage J. O., Gale R. P., Pelz C. J., Sobocinski A. K., et al. Report from the International Bone Marrow Transplant Registry and Autologous Blood and Marrow Transplant Registry—North America. Clin Transpl 1995; 117–27
   Google Scholar
• Sullivan K. M., Weiden P. L., Storb R., Witherspoon R. P., Fefer A., Fisher L., et al. Influence of acute and chronic graft‐versus‐host disease on relapse and survival after bone marrow transplantation from HLA‐identical siblings as treatment of acute and chronic leukemia. Blood 1989; 73: 1720–6
   PubMed Web of Science ®Google Scholar
• Horowitz M., Gale R. P., Sondel P. M., Goldman J. M., Kersey J., Kolb H. J., et al. Graft‐versus‐leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555–62
   PubMed Web of Science ®Google Scholar
• Ringden O., Horowitz M. M. for the Advisory Committee of the International BMT Registry. Graft‐versus‐leukemia reactions in humans. Transplant Proc 1989; 21: 2989–92
   PubMed Web of Science ®Google Scholar
• Kolb H. J., Mittermuller J., Clemm C., Holler E., Ledderose G., Brehm G., et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462–5
   PubMed Web of Science ®Google Scholar
• Kolb H. J., Schattenberg A., Goldman J. M., Hertenstein B., Jacobsen N., Arcese W., et al. Working Party Chronic Leukemia, Graft‐versus‐leukemia effect of donor lymphocyte transfusions in marrow grafted patients: European Group for blood and marrow transplantation. Blood 1995; 86: 2041–50
   PubMed Web of Science ®Google Scholar
• Collins R. H Jr., Shpilberg O., Drobyski W. R., Porter D. L., Giralt S., Champlin R., et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433–44
   PubMed Web of Science ®Google Scholar
• Porter D. L., Roth M. S., McGarigle C., Ferrara J. L., Antin J. H. Induction of graft‐versus‐host disease as immunotherapy for relapsed chronic myeloid leukemia. New Engl J Med 1994; 330: 100–06
   PubMed Web of Science ®Google Scholar
• Mackinnon S., Papadopoulos E. B., Carabassi M. H., Reich L., Collins N. H., Boulad F., et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft‐versus‐leukemia responses from graft‐versus‐host disease. Blood 1995; 86: 1261–8
   PubMed Web of Science ®Google Scholar
• Weiss L., Lubin I., Factorowich Y., Lapidot Z., Reich S., Reisner, et al. Effective graft vs leukemia effects independent of graft vs host disease after T‐Cell depleted allogeneic bone marrow transplantation in a murine model of B Cell leukemia/lymphoma. Role of cell therapy and rIL‐2. J Immunol 1994; 153: 2562–7
   PubMed Web of Science ®Google Scholar
• Slavin S., Weiss L., Morecki S., Weingensberg M. Eradication of murine leukemia with histoincompatible marrow grafts in mice conditioned with total lymphoid irradiation (TLI). Cancer Immunol Immunother 1981; 11: 155–61
   Web of Science ®Google Scholar
• Moscovitch M., Slavin S. Anti‐tumor effects of allogeneic bone marrow transplantation in (NZB/NZW) F1 hybrids with spontaneous lymphosarcoma. J Immunol 1984; 132: 997–1000
   PubMed Web of Science ®Google Scholar
• Slavin S., Nagler A., Naparstek E., Kapelushnik J., Aker M., Cividalli G., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756–63
   PubMed Web of Science ®Google Scholar
• Giralt S., Thall P. F., Khouri I., Wang X., Braunschweig I., Ippolitti C., et al. Melphalan and purine‐analog containing preparative regimens: reduced‐intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97: 631–7
   PubMed Web of Science ®Google Scholar
• Kottaridis P. D., Milligan D. W., Chopra R., Chakraverty R. K., Chakrabarti S., Robinson S., et al. In vivo CAMPATH‐1H prevents graft‐versus‐host disease following nonmyeloablative stem cell transplantation. Blood 2000; 96: 2419–25
   PubMed Web of Science ®Google Scholar
• Sayer H. G., Kroger M., Beyer J., Kiehl M., Klein S. A., Schaefer‐Eckhart K., et al. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplant 2003; 31: 1089–95
   PubMed Web of Science ®Google Scholar
• Bacigalupo A. Third EBMT/AMGEN Workshop on reduced‐intensity conditioning allogeneic hematopoietic stem cell transplants (RIC‐HSCT), and panel consensus. Bone Marrow Transplant 2004; 33: 691–6
   PubMed Web of Science ®Google Scholar
• McSweeney P. A., Niederwieser D., Shizuru J. A., Sandmaier B. M., Molina A. J., Maloney G., et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high‐dose cytotoxic therapy with graft‐versus‐tumor effects. Blood 2001; 97: 3390–400
   PubMed Web of Science ®Google Scholar
• Niederwieser D., Maris M., Shizuru J. A., Petersdorf E., Hegenbart U., Sandmaier B. M., et al. Low‐dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA‐matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003; 101: 1620–9
   PubMed Web of Science ®Google Scholar
• Shapira M. Y., Or R., Resnick I. B., Bitan M., Ackerstein A., Samuel S., et al. A new minimally ablative stem cell transplantation procedure in high‐risk patients not eligible for nonmyeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant 2003; 32: 557–61
   Google Scholar
• Alyea E. P., Kim H. T., Ho V., Cutler C., Gribben J., DeAngelo D. J., et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 2005; 105: 1810–14
   PubMed Web of Science ®Google Scholar
• Diaconescu R., Flowers C. R., Storer B., Sorror M. L., Maris M. B., Maloney D. G., et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA‐matched related donors. Blood 2004; 104: 1550–8
   PubMed Web of Science ®Google Scholar
• Sorror M. L., Maris M. B., Storer B., Sandmaier B. M., Diaconescu R., Flowers C., et al. Comparing morbidity and mortality of HLA‐matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood 2004; 104: 961–8
   PubMed Web of Science ®Google Scholar
• Valcarcel D., Martino R., Sureda A., Canals C., Altes A., Briones J., et al. Conventional versus reduced‐intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies. Eur J Haematol 2005; 74: 144–51
   PubMed Web of Science ®Google Scholar
• Canals C., Martino R., Sureda A., Altes A., Briones J., Subira M., et al. Strategies to reduce transplant‐related mortality after allogeneic stem cell transplantation in elderly patients: Comparison of reduced‐intensity conditioning and unmanipulated peripheral blood stem cells vs a myeloablative regimen and CD34+ cell selection. Exp Hematol 2003; 31: 1039–43
   Google Scholar
• Perez‐Simon J. A., Diez‐Campelo M., Martino R., Brunet S., Urbano A., Caballero M. D., et al. Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft‐versus‐host disease after allogeneic transplantation. Br J Haematol 2005; 130: 394–403
   PubMed Web of Science ®Google Scholar
• Mielcarek M., Martin P. J., Leisenring W., Flowers M. E., Maloney D. G., Sandmaier B. M., et al. Graft‐versus‐host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003; 102: 756–62
   PubMed Web of Science ®Google Scholar
• Vela‐Ojeda J., Garcia‐Ruiz Esparza M. A., Tripp‐Villanueva F., Ayala‐Sanchez M., Delgado‐Lamas J. L., Graces‐Ruiz O., et al. Allogeneic peripheral blood stem cell transplantation using reduced intensity versus myeloablative conditioning regimens for the treatment of leukemia. Stem Cells Dev 2004; 13: 571–9
   PubMed Web of Science ®Google Scholar
• Massenkeil G., Nagy M., Neuburger S., Tamm I., Lutz C., le Coutre P., et al. Survival after reduced‐intensity conditioning is not inferior to standard high‐dose conditioning before allogeneic haematopoietic cell transplantation in acute leukaemias. Bone Marrow Transplant 2005; 36: 683–9
   Google Scholar
• Couriel D. R., Saliba R. M., Giralt S., Khouri I., Andersson B., de Lima M., et al. Acute and chronic graft‐versus‐host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant 2004; 10: 178–85
   PubMed Web of Science ®Google Scholar
• Dreger P., Brand R., Milligan D., Corradini P., Finke J., Lambertenghi D. G., et al. Chronic Leukemia Working Party of the EBMT. Reduced‐intensity conditioning lowers treatment‐related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population‐matched analysis. Leukemia 2005; 19: 1029–33
   PubMed Web of Science ®Google Scholar
• Aoudjhane M., Labopin M., Gorin N. C., Shimoni A., Ruutu T., Kolb H. J., et al. Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005; 19: 2304–12
   PubMed Web of Science ®Google Scholar
• Wong R., Giralt S. A., Martin T., Couriel D. R., Anagnostopoulous A., Hosing C., et al. Reduced intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood 2003; 102: 3052–9
   PubMedGoogle Scholar
• Shapira M. Y., Resnick I. B., Bitan M., Ackerstein A., Samuel S., Elad S., et al. Low transplant related mortality with allogeneic stem cell transplantation in elderly patients. Bone Marrow Transplant 2004; 34: 155–9
   Google Scholar
• Bertz H., Potthoff K., Finke J. Allogeneic stem cell transplantation from related and unrelated donors in older patients with myeloid leukemia. J Clin Oncol 2003; 21: 1480–4
   PubMed Web of Science ®Google Scholar
• Shimoni A., Kroger N., Zabelina T., Ayuk F., Hardan I., Yeshurun M., et al. Hematopoietic stem cell transplantation from unrelated donors in elderly patients (age>55 years) with hematologic malignancies: older age is no longer a contraindication when using a reduced intensity conditioning. Leukemia 2005; 19: 7–12
   PubMed Web of Science ®Google Scholar
• Eibl B., Schwaighofer H., Nachbaur D., Marth C., Gachter A., Knapp R., et al. Evidence for a graft‐versus‐tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 1996; 88: 1501–08
   PubMed Web of Science ®Google Scholar
• Childs R., Chernoff A., Contentin N., Bahceci E., Schrump D., Leitman S., et al. Regression of metastatic renal‐cell carcinoma after nonmyeloablative allogeneic peripheral‐blood stem‐cell transplantation. N Engl J Med 2000; 343: 750–8
   PubMed Web of Science ®Google Scholar
• Nakagawa T., Kami M., Hori A., Kim S. W., Murashinge N., Hamaki T., et al. Allogeneic hematopoietic stem cell transplantation with a reduced‐intensity conditioning regimen for treatment of metastatic renal cell carcinoma: single institution experience with a minimum 1‐year follow‐up. Exp Hematol 2004; 32: 599–606
   PubMed Web of Science ®Google Scholar
• Bay J. O., Fleury J., Choufi B., Bilger K., Tournilhac O., Vey N., et al. Allogeneic hematopoietic stem cell transplantation in ovarian carcinoma: results of five patients. Bone Marrow Transplant 2002; 30: 95–102
   PubMed Web of Science ®Google Scholar
• Ueno N. T., Cheng Y. C., Rondon G., Tannir N. M., Gajewski J. L., Couriel D. R., et al. Rapid induction of complete donor chimerism by the use of a reduced‐intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 2003; 102: 3829–36
   PubMed Web of Science ®Google Scholar
• Carella A. M., Beltrami G., Corsetti M. T., Nati S., Musto P., Scalzulli P., et al. Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer. Lancet 2005; 366: 318–20
   PubMed Web of Science ®Google Scholar
• Kanda Y., Komatsu Y., Akahane M., Kojima S., Asano‐Mori Y., Tada M., et al. Graft‐versus‐tumor effect against advanced pancreatic cancer after allogeneic reduced‐intensity stem cell transplantation. Transplantation 2005; 79: 821–7
   Google Scholar
• Pedrazzoli P., Da Prada G. A., Giorgiani G., Schiavo R., Zambelli A., Giraldi E., et al. Allogeneic blood stem cell transplantation after a reduced‐intensity, preparative regimen: a pilot study in patients with refractory malignancies. Cancer 2002; 94: 2409–15
   PubMed Web of Science ®Google Scholar
• Moscardo F., Martinez J. A., Sanz G. F., Jimenez C., Cervera J., Sanchis J., et al. Graft‐versus‐tumour effect in non‐small‐cell lung cancer after allogeneic peripheral blood stem cell transplantation. Br J Haematol 2000; 111: 708–10
   PubMed Web of Science ®Google Scholar
• Kurokawa T., Fischer K., Bertz H., Hoegerle S., Finke J., Mackensen A. In vitro and in vivo characterization of graft‐versus‐tumor responses in melanoma patients after allogeneic peripheral blood stem cell transplantation. Int J Cancer 2002; 101: 52–60
   Google Scholar
• Godfrey W. R., Krampf M. R., Taylor P. A., Blazar B. R. Ex vivo depletion of alloreactive cells based on CFSE dye dilution, activation antigen selection, and dendritic cell stimulation. Blood 2004; 103: 1158–65
   PubMed Web of Science ®Google Scholar
• Carlen S., Gilljam M., Chambers B. J., Aschan J., Guven H., Ljunggren H. G., et al. A new method for in vitro expansion of cytotoxic human CD3‐ CD56+ natural killer cells. Hum Immunol 2001; 62: 1092–8
   Google Scholar
• Mutis T., Verdijk R., Schrama E., Esendam B., Brand A., Goulmy E. Feasibility of immunotherapy of relapsed leukemia with ex vivo‐generated cytotoxic T lymphocytes specific for hematopoietic system‐restricted minor histocompatibility antigens. Blood 1999; 93: 2336–41
   PubMed Web of Science ®Google Scholar
• Naparstek E. The role of the anti‐CD20 antibody rituximab in hematopoietic stem cell transplantation for non‐Hodgkin's lymphoma. Curr Hematol Rep 2005; 4: 276–83
   Google Scholar
• Nath S. V., Seymour J. F. Cure of a patient with profoundly chemotherapy‐refractory primary mediastinal large B‐cell lymphoma: role of rituximab, high‐dose therapy, and allogeneic stem cell transplantation. Leuk Lymphoma 2005; 46: 1075–9
   PubMed Web of Science ®Google Scholar
• Prigozhina T. B., Elkin G., Khitrin S., Slavin S. Depletion of donor‐reactive cells as a new concept for improvement of mismatched bone marrow engraftment using reduced‐intensity conditioning. Exp Hematol 2004; 32: 1110–17
   PubMedGoogle Scholar